Sachdev G, et al. - In this retrospective interventional study, authors analyzed 134 eyes to estimate the safety of the implantable phakic contact lens (IPCL V1, Caregroup Sight Solutions, India) for correction of myopic astigmatism and myopia. They measured visual acuity (in logMAR) and manifest refraction, slit lamp biomicroscopy, IOP, dilated fundus examination and endothelial cell density at preoperative and 1-, 6- and 12-month postoperative visits. The mean follow-up in the study was 25.66±16.45 months. They observed 0.7% of cases needed surgical intervention whereas cataract was noted as a most common entity. They also found increased IOP in 4 eyes and 2.01%±4.12% of endothelial cell loss over a 1-year follow-up. They observed no visual threatening complexities suggesting IPCL as a safe and efficient therapy for repair of myopia and myopic astigmatism.